Study of AK119 in Subjects With Advanced Solid Tumors

Summary

This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.

Timeline

Start

2021-12-22

Primary completion

2023-05-22

Completion

2023-05-22

Drugs

Indications